Dr. Kulisevsky, director of the Movement Disorders Unit of the Sant Pau Hospital Neurology Service and head of the Parkinson’s Disease and Movement Disorders Research Group at the Sant Pau Research Institute, is the principal investigator and international coordinator of a controlled phase 2 drug study that, for the first time in 20 years, is achieving positive results for cognitive complications in Parkinson’s disease. Sant Pau Hospital has also participated as a patient recruitment centre for the study.
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del...
Horizon ha puesto en funcionamiento una nueva planta dedicada íntegra...
Biotechnology portal in Spain
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Biotech-Spain.com - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory